Hepatitis B Virus
Hepatitis B virus resistance to lamivudine clarified
Published in Hepatitis Weekly, March 13th, 2006
"Lamivudine was the first approved inhibitor of HBV reverse transcriptase (RT). Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment," scientists in France report.
"We extensively characterized the dynamics of HBV quasispecies variant populations in four HBV-infected patients who developed lamivudine resistance. Virological breakthrough was preceded by 2 to 4 months by the emergence of quasispecies variants bearing amino acid substitutions at RT position 204, i.e., within the YMDD catalytic motif...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-03-13)
More Articles from Hepatitis Weekly
- Hepatitis C Virus
Bottlenecking affects HCV evolution during sexually transmitted acute resolving infection - Hepatitis C Virus
Detection of HCV viremia predicts post-treatment relapse - Hepatitis C Virus
Hepatitis C virus envelope glycoprotein E2 residues contribute to virus entry - Hepatitis C Virus
Hepatitis C virus induces toll-like receptor 4 expression - Autoimmune Disease
Rituximab is highly effective in autoimmune lymphoproliferative disorders - Blood Transfusions
Blood transfusions may transmit occult hepatitis B virus to adults and children - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
